In the US, there is currently a shortage of injectable opioids used in hospitals for the management of pain due to a significant supplier in the market temporarily ceasing manufacturing. We have made investments to significantly increase capacity for these products at our New Jersey facility to make up for the large drop-in supply that is currently impacting patient care.
We are subject to Drug Enforcement Agency (DEA) quotas on controlled substances (such as opioids) based on the amounts used and sold in the previous year. We have increased our manufacturing capacity and believe we can now address the current shortages pending increased quota allowances from the DEA. We are committed to helping provide hospitals and doctors with the medicines they need to best treat their patients.
We have taken additional steps to meet the increased customer demand, including investing in additional headcount, overtime and adjusted production schedules. We will continue to work closely with our customers to manage this challenging situation.